These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30187562)

  • 21. Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission.
    Molander P; Färkkilä M; Salminen K; Kemppainen H; Blomster T; Koskela R; Jussila A; Rautiainen H; Nissinen M; Haapamäki J; Arkkila P; Nieminen U; Kuisma J; Punkkinen J; Kolho KL; Mustonen H; Sipponen T
    Inflamm Bowel Dis; 2014 Jun; 20(6):1021-8. PubMed ID: 24798636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Ulcerative colitis and Crohn's disease].
    Matsuoka K; Hibi T
    Nihon Rinsho; 2005 May; 63 Suppl 5():507-11. PubMed ID: 15954400
    [No Abstract]   [Full Text] [Related]  

  • 23. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.
    Deshpande AR; Strobel S
    Aliment Pharmacol Ther; 2011 Sep; 34(5):586. PubMed ID: 21806647
    [No Abstract]   [Full Text] [Related]  

  • 24. [Not Available].
    Novacek G; Dejaco C; Gröchenig HP; Högenauer C; Knoflach P; Miehsler W; Moschen A; Petritsch W; Vogelsang H; Tilg H
    Z Gastroenterol; 2016 May; 54(5):456-67. PubMed ID: 26982099
    [No Abstract]   [Full Text] [Related]  

  • 25. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
    Schreiber S; Dignass AU; Hartmann H; Kruis W; Rogler G; Siegmund B; Stallmach A; Witte C; Bokemeyer B
    Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease.
    Kopylov U; Rosenfeld G; Bressler B; Seidman E
    Inflamm Bowel Dis; 2014 Apr; 20(4):742-56. PubMed ID: 24562174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Damage-associated molecular patterns in inflammatory bowel disease: From biomarkers to therapeutic targets.
    Nanini HF; Bernardazzi C; Castro F; de Souza HSP
    World J Gastroenterol; 2018 Nov; 24(41):4622-4634. PubMed ID: 30416310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biologics for inflammatory bowel diseases in the Asia-Pacific: can we afford to use them, can we afford not to?
    Gearry RB; Irving PM
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1160-2. PubMed ID: 19682189
    [No Abstract]   [Full Text] [Related]  

  • 29. [Inflammatory bowel disease].
    Patuto N; Beglinger C
    Praxis (Bern 1994); 2013 Aug; 102(17):1046-52. PubMed ID: 23965717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transmissible agents in inflammatory bowel disease: 1980.
    Beeken WL
    Med Clin North Am; 1980 Nov; 64(6):1021-35. PubMed ID: 7007757
    [No Abstract]   [Full Text] [Related]  

  • 31. [Golimumab Therapy in Ulcerative Colitis].
    Moon W
    Korean J Gastroenterol; 2016 Feb; 67(2):64-73. PubMed ID: 26907481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poor correlation between acute phase reactants and intestinal involvement in patients with onset of Crohn's disease under treatment with an interleukin-6 inhibitor due to seronegative arthropathy.
    Zacarías Martínez L; Mateo Soria L; Mañosa Círia M; Clos Parals A; Cabré Gelada E; Domènech Morral E
    Gastroenterol Hepatol; 2016 Dec; 39(10):670-672. PubMed ID: 26589538
    [No Abstract]   [Full Text] [Related]  

  • 33. Mucosal healing in inflammatory bowel disease: treatment efficacy and predictive factors.
    Papi C; Fascì-Spurio F; Rogai F; Settesoldi A; Margagnoni G; Annese V
    Dig Liver Dis; 2013 Dec; 45(12):978-85. PubMed ID: 24018244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Biological therapy in children with inflammatory bowel syndrome (clinical cases)].
    Alieva ÉI
    Eksp Klin Gastroenterol; 2014; (1):110-2. PubMed ID: 25518466
    [No Abstract]   [Full Text] [Related]  

  • 35. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease.
    Boschetti G; Garnero P; Moussata D; Cuerq C; Préaudat C; Duclaux-Loras R; Mialon A; Drai J; Flourié B; Nancey S
    Inflamm Bowel Dis; 2015 Feb; 21(2):331-6. PubMed ID: 25625487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort.
    Hiroz P; Vavricka SR; Fournier N; Safroneeva E; Pittet V; Rogler G; Schoepfer AM;
    Scand J Gastroenterol; 2014 Oct; 49(10):1207-18. PubMed ID: 25120029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Colitis ulcerosa and enterocolitis regionalis Crohn].
    Fahrländer H; Shalev E
    Dtsch Med Wochenschr; 1974 Nov; 99(44):2235-40. PubMed ID: 4609717
    [No Abstract]   [Full Text] [Related]  

  • 38. [Treatment of colitis ulcerosa and Crohn's disease].
    Kovács A
    Orv Hetil; 2006 Apr; 147(16):755-8. PubMed ID: 16711262
    [No Abstract]   [Full Text] [Related]  

  • 39. Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation.
    Kolho KL; Korpela K; Jaakkola T; Pichai MV; Zoetendal EG; Salonen A; de Vos WM
    Am J Gastroenterol; 2015 Jun; 110(6):921-30. PubMed ID: 25986361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of Escherichia coli Nissle in maintaining disease remission in inflammatory bowel disease.
    Buldukoglu OC
    J Gastrointestin Liver Dis; 2024 Jun; 33(2):280-281. PubMed ID: 38944860
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.